Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion

Abstract

The efficacy and safety of recombinant tissue plasminogen activator (rtPA) need to be improved due to its low bioavailability and requirement of large dose administration. The purpose of this study was to develop a fibrin-targeted nanoparticle (NP) drug delivery system for thrombosis combination therapy. We conjugated rtPA to poly(ethylene glycol)- poly(e-caprolactone) (PEG-PCL) nanoparticles (rtPA-NP) and investigated its physicochemical characteristics such as particle size, zeta potential, enzyme activity of conjugated rtPA and its storage stability at 4°C. The thrombolytic activity of rtPA-NP was evaluated in vitro and in vivo as well as the half-life of rtPA-NP, the properties to fibrin targeting and its influences on systemic hemostasis in vivo. The results showed that rtPA-NP equivalent to 10% of a typical dose of rtPA could dissolve fibrin clots and were demonstrated to have a neuroprotective effect after focal cerebral ischemia as evidenced by decreased infarct volume and improved neurological deficit (P<0.001). RtPA-NP did not influence the in vivo hemostasis or coagulation system. The half-life of conjugated rtPA was shown to be approximately 18 times longer than that of free rtPA. These experiments suggested that rtPA-conjugated PEG-PCL nanoparticles might be a promising fibrin-targeted delivery system for a combination treatment of thrombosis.

Keywords

recombinant tissue plasminogen activator / thrombolysis / nanoparticles / drug delivery system

References

[1] RaskobGE, AngchaisuksiriP, BlancoAN, et al.. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vase Biol, 2014, 34(11): 2363-2371

[2] StollG, KleinschnitzC, NieswandtB. Molecular mechanisms of thrombus formation in ischemic stroke: novel insights and targets for treatment. Blood, 2008, 112(9): 3555-3562

[3] RhaJH, SaverJL. The Impact of recanalization on ischemic stroke outcome. Stroke, 2007, 38(3): 967-973

[4] ZhuH, FanX, YuZ, et al.. Annexin A2 combined with low-dose tPA improves thrombolytic therapy in a rat model of focal embolic stroke. J Cereb Blood Flow Metab, 2010, 30(6): 1137-1146

[5] MackmanN. Triggers, targets and treatments for thrombosis. Nature, 2008, 451(7181): 914-918

[6] FurieB, FurieBC. Mechanisms of thrombus formation. N Engl J Med, 2008, 359(9): 938-949

[7] TalianiMR, BecattiniC, AgnelliG, et al.. Duration of anticoagulant treatment and recurrence of venous thromboembolism in patients with and without thrombophilic abnormalities. Thromb Haemost, 2009, 101(3): 596-598

[8] ZamanluM, FarhoudiM, EskandaniM, et al.. Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke. J Drug Target, 2018, 26(2): 95-109

[9] ZhouJ, GuoD, ZhangY, et al.. Construction and evaluation of Fe(3)0(4)-based PLGA nanoparticles carrying rtPA used in the detection of thrombosis and in targeted thrombolysis. ACS Appl Mater Interfaces, 2014, 6(8): 5566-5576

[10] ZhangB, JiangT, SheX, et al.. Fibrin degradation by rtPA enhances the delivery of nanotherapeutics to A549 tumors in nude mice. Biomaterials, 2016, 96: 63-71

[11] KimBYS, RutkaJT, ChanWCW. Nanomedicine. N Engl J Med, 2010, 363(25): 2434-2443

[12] LongstaffC, WilliamsS, ThelwellC. Fibrin binding and the regulation of plasminogen activators during thrombolytic therapy. Cardiovasc Hematol Agents Med Chem, 2008, 6(3): 212-223

[13] TanswellP, TebbeU, NeuhausKL, et al.. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol, 1992, 19(5): 1071-1075

[14] TadayonA, JamshidiR, EsmaeiliA. Delivery of tissue plasminogen activator and streptokinase magnetic nanoparticles to target vascular diseases. Int J Pharm, 2015, 495(1): 428-438

[15] TanswellP, ModiN, CombsD, et al.. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet, 2002, 41(15): 1229-1245

[16] PilchJ, BrownDM, KomatsuM, et al.. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci USA, 2006, 103(8): 2800-2804

[17] XingB, ChenH, ZhangM, et al.. Ischemic postconditioning inhibits apoptosis after focal cerebral ischemia/reperfusion injury in the rat. Stroke, 2008, 39(8): 2362-2369

[18] TsubokawaT, JadhavV, SolarogluI, et al.. Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Stroke, 2007, 38(3): 1057-1062

[19] SwansonRA, MortonMT, Tsao-WuG, et al.. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab, 1990, 10(2): 290-293

[20] KurataM, SasayamaY, YamasakiN, et al.. Mechanism for shortening PT and APTT in dogs and rats—effect of fibrinogen on PT and APTT. J Toxicol Sci, 2003, 28(5): 439-443

[21] ToyodaK, YasakaM, IwadeK, et al.. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke, 2008, 39(6): 1740-1745

[22] FitzmauriceDA, BlannAD, LipGY. Bleeding risks of antithrombotic therapy. BMJ, 2002, 325(7368): 828-831

[23] StollP, BasslerN, HagemeyerCE, et al.. Targeting ligand-induced binding sites on GPIIb/IIIa via singlechain antibody allows effective anticoagulation without bleeding time prolongation. Arterioscler Thromb Vase Biol, 2007, 27(5): 1206-1212

[24] PeterK, GraeberJ, KipriyanovS, et al.. Construction and functional evaluation of a single-chain antibody fusion protein with fibrin targeting and thrombin inhibition after activation by factor Xa. Circulation, 2000, 101(10): 1158-1164

[25] LanzaGM, WallaceKD, ScottMJ, et al.. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation, 1996, 94(12): 3334-3340

[26] KorinN, KanapathipillaiM, MatthewsBD, et al.. Shear-activated nanotherapeutics for drug targeting to obstructed blood vessels. Science, 2012, 337(6095): 738-742

[27] MaYH, WuSY, WuT, et al.. Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. Biomaterials, 2009, 30(19): 3343-3351

[28] YangS, KrugSM, HeitmannJ, et al.. Analgesie drug delivery via recombinant tissue plasminogen activator and microRNA-183-triggered opening of the blood-nerve barrier. Biomaterials, 2016, 82: 20-33

[29] GershKC, ZaitsevS, CinesDB, et al.. Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent. Blood, 2011, 117(18): 4964-4967

[30] ChawlaJS, AmijiMM. Biodegradable poly(epsilon -caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm, 2002, 249(1-2): 127-138

[31] FangF, GongC, QianZ, et al.. Honokiol nanoparticles in thermosensitive hydrogel: Therapeutic effects on malignant pleural effusion. ACS Nano, 2009, 3(12): 4080-4088

[32] CalvoP, GouritinB, ChacunH, et al.. Long-circulating PEGylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res, 2001, 18(8): 1157-1166

[33] MurcianoJC, MedinillaS, EslinD, et al.. Prophylactic fibrinolysis through selective dissolution of nascent clots by tPA-carrying erythrocytes. Nat Biotechnol, 2003, 21(8): 891-896

[34] KimJY, KimJK, ParkJS, et al.. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials, 2009, 30(29): 5751-5756

[35] ConnollyE Jr, WinfreeCJ, SpringerTA, et al.. Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest, 1996, 97(1): 209-216

[36] del ZoppoGJ, MabuchiT. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab, 2003, 23(8): 879-894

[37] OkadaY, CopelandBR, FitridgeR, et al.. Fibrin contributes to microvascular obstructions and parenchymal changes during early focal cerebral ischemia and reperfusion. Stroke, 1994, 25(9): 1847-1853

[38] GangulyK, GoelMS, KrasikT, et al.. Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo. J Pharmacol Exp Ther, 2006, 316(3): 1130-1136